BidaskClub upgraded shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) from a buy rating to a strong-buy rating in a report issued on Wednesday, July 19th.
A number of other equities analysts have also recently weighed in on FOLD. Zacks Investment Research raised shares of Amicus Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 21st. Leerink Swann reissued an outperform rating and issued a $15.00 price objective on shares of Amicus Therapeutics in a research report on Thursday, March 30th. Robert W. Baird reissued an outperform rating and issued a $12.00 price objective (up from $10.00) on shares of Amicus Therapeutics in a research report on Wednesday, May 17th. Bank of America Corporation decreased their price objective on shares of Amicus Therapeutics from $10.00 to $9.00 and set a buy rating for the company in a research report on Thursday, May 25th. Finally, Chardan Capital reissued a buy rating and issued a $12.50 price objective on shares of Amicus Therapeutics in a research report on Thursday, June 1st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $13.42.
Shares of Amicus Therapeutics (FOLD) opened at 13.62 on Wednesday. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $14.05. The company has a 50 day moving average price of $11.40 and a 200 day moving average price of $8.12. The firm’s market cap is $1.95 billion. Amicus Therapeutics also saw some unusual options trading activity on Monday. Traders acquired 11,013 call options on the company. This is an increase of 666% compared to the typical volume of 1,438 call options.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.03. During the same quarter in the previous year, the firm earned ($0.40) earnings per share. On average, analysts forecast that Amicus Therapeutics will post ($1.37) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://stocknewstimes.com/2017/08/08/amicus-therapeutics-inc-nasdaqfold-upgraded-by-bidaskclub-to-strong-buy-updated-updated.html.
In other news, insider Jay Barth sold 30,000 shares of the stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $10.00, for a total transaction of $300,000.00. Following the transaction, the insider now owns 64,184 shares of the company’s stock, valued at $641,840. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Hung Do sold 29,914 shares of the stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $8.00, for a total transaction of $239,312.00. Following the transaction, the insider now directly owns 474,438 shares in the company, valued at approximately $3,795,504. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of FOLD. Teacher Retirement System of Texas boosted its position in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new position in shares of Amicus Therapeutics during the second quarter worth about $111,000. Aperio Group LLC boosted its position in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 1,663 shares in the last quarter. Princeton Alpha Management LP acquired a new position in shares of Amicus Therapeutics during the first quarter worth about $106,000. Finally, Creative Planning boosted its position in shares of Amicus Therapeutics by 56.2% in the first quarter. Creative Planning now owns 16,400 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 5,900 shares in the last quarter.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
